Appointment of Non-Executive Director

RNS Number : 7756Z

Redx Pharma plc

27 January 2022

 

REDX PHARMA PLC

("Redx" or "the Company")

Appointment of Non-Executive Director

Dr Rob Scott brings extensive clinical development and regulatory experience to Board

Alderley Park, UK, 27 January 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, is pleased to announce the appointment of Dr Rob Scott as a Non-Executive Director with immediate effect.

Dr Scott brings extensive clinical development and regulatory experience to the Board, having held senior leadership positions in global pharma for over thirty years. Most recently, Dr Scott retired as Chief Medical Officer at AbbVie, where he oversaw 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq. Recent prior experience includes the roles of Vice President of Global Development at Amgen and Industry Representative on the US Food and Drug Administration Cardiac and Renal Drug Advisory Committee. Dr Scott is currently on the boards of ArisGlobal, Confo Therapeutics, Draupnir Bio, Windtree Therapeutics and Oncospherix as well as several scientific advisory boards. Dr Scott is a Zimbabwean born physician and a graduate of the University of Cape Town.

Dr Jane Griffiths, Chair of the Board of Redx, commented : "We are excited to welcome Rob onto the Redx Board. As we build our portfolio of clinical stage assets, Rob will bring a clinical development and regulatory perspective to help shape our programmes, particularly in the US where he has been based for almost 30 years. The Board and I look forward to working with Rob to ensure that we continue to grow Redx into a successful biotech company focused on the treatment of cancer and fibrotic disease." 

Dr Rob Scott commented "I am delighted to be joining the Redx Board, especially at a time where there is real momentum with the Company's cancer and fibrosis assets in the clinic. I look forward to working with the Board as Redx continues to progress its exciting drug candidates through the clinical development process."

Following Dr Scott's appointment, the Board will be comprised of eight directors, five of whom, including the Chair, are independent Non-Executive Directors (Dr Jane Griffiths, Peter Presland, Dr Bernhard Kirschbaum, Sarah Gordon Wild and Dr Rob Scott), two shareholder representative Non-Executive Directors (Natalie Berner and Dr Thomas Burt) and Redx's Chief Executive Officer, Lisa Anson.

Additional information:

The following information is being disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies:

Full name and age: Robert Andrew Donald Scott, aged 68

Dr Scott does not hold any shares in the Company

Dr Scott holds or has previously held the following directorships:

C urrent directorships and/or partnerships	Former directorships and/or partnerships (within the last five years):
Windtree Therapeutics Inc Confo Therapeutics NV ArisGlobal LLC Draupnir Bio ApS Oncospherix	Chicago Council on Science and Technology TransCelerate BioPharma Inc Kanan Therapeutics Inc

For further information, please contact:
Redx Pharma Plc  UK Headquarters Lisa Anson, Chief Executive Officer	T: [phone]
US Office Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)	T: [phone]
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Satheesh Nadarajah/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker)	T: [phone]
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting	T: [phone]
Simon Conway/ Ciara Martin

About Redx Pharma Plc  

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/    

 

END

 

 

BOABKABDBBKBKDB